Media coverage about Fortress Biotech (NASDAQ:FBIO) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Fortress Biotech earned a media sentiment score of 0.03 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 44.0829897216692 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the headlines that may have effected Accern’s analysis:
- Checkpoint Therapeutics to Participate in March Investor Conferences – EconoTimes (econotimes.com)
- Mustang Bio to Present at the 255th American Chemical Society National Meeting & Exposition – GlobeNewswire (press release) (globenewswire.com)
- Fortress Biotech to Present at Oppenheimer’s 28th Annual Healthcare Conference – GlobeNewswire (press release) (globenewswire.com)
- Fortress Biotech to Present at Oppenheimer’s 28th Annual Healthcare Conference (finance.yahoo.com)
- Fortress Biotech (FBIO) Upgraded at BidaskClub (americanbankingnews.com)
A number of equities analysts recently commented on FBIO shares. ValuEngine upgraded shares of Fortress Biotech from a “sell” rating to a “hold” rating in a research note on Thursday, March 1st. BidaskClub upgraded shares of Fortress Biotech from a “sell” rating to a “hold” rating in a research note on Sunday. HC Wainwright set a $11.00 target price on shares of Fortress Biotech and gave the stock a “buy” rating in a research note on Tuesday, December 12th. Zacks Investment Research upgraded shares of Fortress Biotech from a “sell” rating to a “hold” rating in a research note on Tuesday, February 6th. Finally, B. Riley started coverage on shares of Fortress Biotech in a research note on Wednesday, February 28th. They set a “buy” rating and a $10.00 target price for the company. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $10.80.
In related news, SVP George Avgerinos sold 12,000 shares of the business’s stock in a transaction on Thursday, December 14th. The shares were sold at an average price of $3.55, for a total value of $42,600.00. Following the completion of the sale, the senior vice president now directly owns 352,495 shares of the company’s stock, valued at $1,251,357.25. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 33.30% of the stock is owned by insiders.
TRADEMARK VIOLATION NOTICE: “Fortress Biotech (FBIO) Receives Daily Coverage Optimism Rating of 0.03” was originally reported by BBNS and is owned by of BBNS. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://baseballnewssource.com/2018/03/14/fortress-biotech-fbio-receives-daily-coverage-optimism-rating-of-0-03/2028975.html.
Fortress Biotech Company Profile
Fortress Biotech, Inc, formerly Coronado Biosciences, Inc, is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products.
Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.